Arkadios Wealth Advisors Sells 1,122 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Arkadios Wealth Advisors trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 60.4% in the third quarter, Holdings Channel reports. The fund owned 737 shares of the biopharmaceutical company’s stock after selling 1,122 shares during the quarter. Arkadios Wealth Advisors’ holdings in Gilead Sciences were worth $46,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Gilead Sciences by 14.4% during the second quarter. BlackRock Inc. now owns 115,834,270 shares of the biopharmaceutical company’s stock valued at $8,912,289,000 after acquiring an additional 14,619,279 shares during the last quarter. Quantamental Technologies LLC raised its position in shares of Gilead Sciences by 68.4% in the 2nd quarter. Quantamental Technologies LLC now owns 20,323 shares of the biopharmaceutical company’s stock worth $1,564,000 after acquiring an additional 8,255 shares in the last quarter. Rathbone Brothers plc lifted its stake in shares of Gilead Sciences by 11.3% in the 2nd quarter. Rathbone Brothers plc now owns 9,855 shares of the biopharmaceutical company’s stock valued at $758,000 after purchasing an additional 1,004 shares during the period. TIAA FSB increased its holdings in Gilead Sciences by 4.0% in the third quarter. TIAA FSB now owns 38,958 shares of the biopharmaceutical company’s stock worth $2,462,000 after purchasing an additional 1,481 shares in the last quarter. Finally, FMR LLC lifted its stake in Gilead Sciences by 14.4% in the second quarter. FMR LLC now owns 12,602,538 shares of the biopharmaceutical company’s stock valued at $969,640,000 after buying an additional 1,582,739 shares during the period. 77.87% of the stock is currently owned by institutional investors.
Several analysts have recently weighed in on GILD shares. Piper Sandler lowered their price objective on shares of Gilead Sciences from $95.00 to $84.00 and set an “overweight” rating for the company in a research note on Thursday, October 29th. SVB Leerink lowered their target price on shares of Gilead Sciences from $88.00 to $79.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a report on Wednesday, September 30th. They set a “buy” rating and a $78.00 price target on the stock. TheStreet lowered shares of Gilead Sciences from a “b” rating to a “c” rating in a research note on Thursday, July 30th. Finally, Oppenheimer upped their target price on Gilead Sciences from $90.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and ten have given a buy rating to the stock. Gilead Sciences has an average rating of “Hold” and a consensus target price of $75.74.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.90 by $0.21. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 6.63 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.53%. The ex-dividend date of this dividend is Monday, December 14th. Gilead Sciences’s payout ratio is currently 44.30%.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: How Investors Use a Balance Sheet
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.